Kolumne, ORE

Original-Research: UBM Development AG - von NuWays AG Einstufung von NuWays AG zu UBM Development AG Unternehmen: UBM Development AG ISIN: AT0000815402 Anlass der Studie: Update Empfehlung: BUY seit: 09.02.2024 Kursziel: 31.00 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: Analyst: Philipp Sennewald Off to a good start / Muted Q4'23 expected; chg Yesterday, UBM announced to have received the building permit for the Timber Peak project in Mainz.

09.02.2024 - 09:56:31

Original-Research: UBM Development AG (von NuWays AG): BUY


Original-Research: UBM Development AG - von NuWays AG

Einstufung von NuWays AG zu UBM Development AG

Unternehmen: UBM Development AG
ISIN: AT0000815402

Anlass der Studie: Update
Empfehlung: BUY
seit: 09.02.2024
Kursziel: 31.00
Kursziel auf Sicht von: 12 Monaten
Letzte Ratingänderung: 
Analyst: Philipp Sennewald

Off to a good start / Muted Q4'23 expected; chg
 
Yesterday, UBM announced to have received the building permit for the
Timber Peak project in Mainz. Once completed, the 12-storey-building will
exceed a height of 40 metres and will have c. 9,500 sqm gross floor area.
The building will be equipped with heat pumps, heating and cooling panels,
EV-charging for up to 40 car parking spaces, and intelligent building
automation technology which is recording consumption and energy efficiency
data systematically. Hence, users will be able to de facto automatically
fulfil the reporting obligations for the EU Taxonomy.
 
While construction is set to kick off end of February, the project is
expected to be completed in Q2'25e. As the window for forward deals is
almost closed at the moment, we do not estimate a revenue contribution
before Q3 '25e. The proceeds are seen in the range of EUR 60-65m (eNuW).
 
Muted Q4e. UBM is expected to publish FY23 prelims in early March (final
FY23 figures on April 11th), which look set to come in muted with sales of
EUR 87.9m (eNuW; eCons: EUR 97.6m) and an EBT of EUR -23.6m (eNuW; eCons: EUR
-21.4m). Mind you, that UBM did not execute major sales in 2023 given the
standstill on the real estate transaction market. Hence, sales were mainly
stemming from smaller disposals as well construction progress on projects
already sold (POC). Importantly, our FY '23e EBT estimate is still subject
to a certain degree of uncertainty which is due to the outcome of the YE
impairment test of the standing assets portfolio.
 
Macro headwinds are starting to ease. After six quarters of decreasing
transaction volumes, we observed first sequential improvements in Q3 (+11%
qoq) that continued in Q4 (+10% qoq) in Germany's Top-7. Paired with
declining financing rates (10y EUR swap rate is -81bps since 10/23) this
indicates that the trough has been reached. Yet, a slow but steady recovery
appears more likely than a rapid upswing, in our view. For UBM, this could
offer the opportunity to sell the Timber Pioneer, which would generate
proceeds of EUR 150m (eNuW; 75% UBM share). However, amid the still high
uncertainty, we factor only a 50% likelihood of this happening and leading
to our estimate of EUR 176m sales in FY24e (eCons: EUR 167m) and an EBT of EUR
18.3m (eCons: EUR 24.6m).
 
Given the compelling mid-term prospects as well as easing macros, the stock
remains a BUY with an unchanged PT of EUR 31.00 based on DDM.

Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/28853.pdf
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.

Kontakt für Rückfragen
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.
Kontakt für Rückfragen
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++

-------------------übermittelt durch die EQS Group AG.-------------------


Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. 
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

@ dpa.de

Weitere Meldungen

Original-Research: Nynomic AG (von Montega AG): Kaufen Original-Research: Nynomic AG - von Montega AG Einstufung von Montega AG zu Nynomic AG Unternehmen: Nynomic AG ISIN: DE000A0MSN11 Anlass der Studie: Update Empfehlung: Kaufen seit: 10.05.2024 Kursziel: 47,00 EUR (zuvor: 48,00 EUR) Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: - Analyst: Miguel Lago Mascato Q1: Solider Jahresauftakt - Steigerung der ausgezeichneten H2/23-Performance & M&A-Newsflow erwartet Nynomic hat Mittwoch Q1-Zahlen veröffentlicht, die eine spürbare Steigerung ggü. (Boerse, 10.05.2024 - 16:16) weiterlesen...

Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH)... Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to MPH Health Care AG Company Name: MPH Health Care AG ISIN: DE000A289V03 Reason for the research: Vorläufige Ergebnisse 2023 Recommendation: Kaufen from: 10.05.2024 Target price: EUR81 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V03) veröffentlicht. (Boerse, 10.05.2024 - 12:41) weiterlesen...

Original-Research: Knaus Tabbert AG (von First Berlin Equity Research GmbH): ... Original-Research: Knaus Tabbert AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Knaus Tabbert AG Company Name: Knaus Tabbert AG ISIN: DE000A2YN504 Reason for the research: Dreimonatsbericht Recommendation: Kaufen from: 10.05.2024 Target price: EUR86 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu Knaus Tabbert AG (ISIN: DE000A2YN504) veröffentlicht. (Boerse, 10.05.2024 - 11:46) weiterlesen...

Original-Research: ZEAL Network SE (von NuWays AG): Kaufen Original-Research: ZEAL Network SE - from NuWays AG Classification of NuWays AG to ZEAL Network SE Company Name: ZEAL Network SE ISIN: DE000ZEAL241 Reason for the research: Recommendation: Kaufen from: 10.05.2024 Target price: EUR 53.00 Target price on sight of: 12 Monaten Last rating change: Analyst: Henry Wendisch Staggering Q1 kicks off new growth phase; chg est. (Boerse, 10.05.2024 - 09:07) weiterlesen...

Original-Research: Nynomic AG (von NuWays AG): Kaufen Original-Research: Nynomic AG - from NuWays AG Classification of NuWays AG to Nynomic AG Company Name: Nynomic AG ISIN: DE000A0MSN11 Reason for the research: Update Recommendation: Kaufen from: 10.05.2024 Target price: EUR 52.00 Target price on sight of: 12 Monaten Last rating change: Analyst: Christian Sandherr Solid start into FY24 despite challenging end markets Topic: Nynomic published a solid start into the year with order intake returning to growth for the first time since Q3 2022. (Boerse, 10.05.2024 - 09:06) weiterlesen...

Original-Research: R. STAHL AG (von NuWays AG): Kaufen. STAHL AG - from NuWays AG Classification of NuWays AG to R. Original-Research: R. (Boerse, 10.05.2024 - 09:02) weiterlesen...